Disease modifiers may take over PAH landscape, says Cereno CEO
There is a major shift away from vasodilator therapy in pulmonary arterial hypertension (PAH), with more disease-modifying therapies entering the space. In an exclusive interview with Pharmaceutical Technology, Cereno Scientific’s CEO Sten Sörensen said …